Med. praxi. 2012;9(1):10-12
News in the treatment of diabetes - linagliptin
- 3. interní klinika VFN a 1. LF UK, Praha
Linagliptin is a novel oral antidiabetic drug from dipeptidyl peptidase-4 (DPP-4) inhibitor class intended for type 2 diabetic patients.
Linagliptin offers similar benefits of DPP-4 inhibitors such as lowering blood sugar with low risk of hypoglycaemia, improving diabetes
control, weight neutrality and good gastrointestinal tolerability. The additional advantage of linagliptin is no dose adjustment for
diabetic patients with kidney or liver impairment. Linagliptin is approved in the EU under the trade name Trajenta in combination with
metformin, metformin plus sulphonylurea or as a monotherapy in patients with intolerance to metformin.
Keywords: linagliptin, oral antidiabetic drugs, type 2. diabetes mellitus
Published: February 13, 2012 Show citation
References
- Holman RR, Paul SK, Bethel MA, et al. Long-term followup after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359(15): 1565-1576.
Go to original source... 
Go to PubMed... - Drucker DJ, Sherman SI, Bergenstal RM, et al. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 2011; 96(7): 2027-2031. Go to original source... Go to PubMed...
- Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodiumglucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011; 32(4): 515-531. Go to original source... Go to PubMed...
- Ahrén B. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care 2007; 30(6): 1344-1350. Go to original source... Go to PubMed...
- Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13(10): 939-946. Go to original source... Go to PubMed...
- Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of ?-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011; 13(3): 258-267. Go to original source... Go to PubMed...
- Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebocontrolled study. Diabetes Obes Metab 2011; 13(1): 65-74. Go to original source... Go to PubMed...
- Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med 2010; 27(12): 1409-1419. Go to original source... Go to PubMed...
- Haak T, Meinicke T, Jones R, et al. Combination of Linagliptin and Metformin Improves Glycemic Control in Type 2 Diabetes: A Randomized Trial with an Open-Label Arm in Patients with Poor Glycemic Control. 71th Scientific Sessions of the ADA, San Diego, California 2011; Oral presentation 279.
- Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24week randomized study. Diabet Med 2011; 28(11): 1352-1361. Go to original source... Go to PubMed...
- Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011; 13(7): 653-661. Go to original source... Go to PubMed...
- Lewin AJ, Arvay L, Liu D, et al. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. 46th Annual Meeting of the EASD, Stockholm, Sweden 2010; Poster 821-P.
- Gallwitz B, Uhlig-Laske B, Bhattacharaya S, et al. Linagliptin Has Similar Efficacy to Glimepiride but Improved Cardiovascular Safety over 2 Years in Patients with Type 2 Diabetes Inadequately Controlled on Metformin. 71th Scientific Sessions of the ADA, San Diego, California 2011; Late Breaker 39.
- Johansen O-E, Neubacher D, von Eynatten M, et al. CV Risk with Linagliptin in Patients with Type 2 Diabetes: A PreSpecified, Prospective, and Adjudicated Meta-Analysis from a Large Phase III Program. 71th Scientific Sessions of the ADA, San Diego, California 2011; Late Breaker 30.
- Trajenta (linagliptin). EMA Summary of Product Characteristics 2011, www.ema.europa.eu.
- Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003; 12(1): 87-100. Go to original source... Go to PubMed...
- Schernthaner G. Kidney disease in diabetology: lessons from 2010. Nephrol Dial Transplant 2011; 26(2): 454-457. Go to original source... Go to PubMed...